The study investigated the pharmacodynamism and mechanism of Chinese medicinal formula-Huiru Yizeng Yihao (NO.1 HRYZ) on the model rats of hyperpro-lactinemia and the model rats of hyperplasia of mammary gland (HMG), and studied the internal connection between hyperprolactinemia and HMG.. The hyperprolactinemia rat models were established by injecting metoclopramide dihydrochloride in the back of rats. The model rat of HMG was prepared by injecting estradiol in the thigh muscle of the rats and progesterone consecutively, while the tails of rats were clipped with tongs. Rats were treated with either NO.1 HRYZ or positive control drugs for four weeks. The concentrations of sex hormone in rat serum were examined using ELISA kits, and the morphology of mammary gland tissue in all group rats was observed with microscope. NO.1 HRYZ significantly decreased prolactin (PRL) and increased estradiol (E 2 ), progesterone (P), follicle stimulating hormone (FSH), luteinizing hormone (LH) concentrations of hyperprolactinemia rats. It decreased E 2, PRL, FSH, gonadotropin-releasing hormone (GnRH), 5-hydroxytryptamine (5-HT) and increased P concentrations of HMG rat. It also eliminated hyperplasia of lobules and gland alveolus compared with the model group. Treatment with NO.1 HRYZ could significantly regulate the sex hormone disorder of hyperprolactinemia and HMG rat models, and could eliminate the formation of HMG. Hyperprolactinemia was closely correlated with HMG, and hyperprolactinemia promoted the formation of HMG.
Chemical drugs are used in treating hyperprolactinemia or HMG, but they always bring many side effects such as menstrual disorder, and the relapse rate is very high. Bromocriptine and cabergoline are effective in curing hyperprolactinemia, but 12% of patients cannot endure bromocriptine (Webster et al., 1994) , and they are expensive (Mah and Webster, 2002) . Hormone drugs such as progesterone or testosterone propionate can fight against increased oestrogen to regulate the balance of hormone in curing HMG (Fallois et al., 1995) . Tan (Tan et al., 2003) found that tamoxifen could significantly relieve the symptom of HMG, but it still had some side effects such as gastrointestinal reaction, vomit or diarrhoea, menstrual disorder, neuropsychiatric symptom, headache or vertigo. Hence, patients often seek herbal therapies outside of the traditional approaches. Chinese medicinal formula No.1 HRYZ has the effect of regulating endocrine disorder. It is widely used in China for the treatment of hyperprolactinemia and HMG and has produced a favourable effect.
The objective of the study is to investigate the pharmacodynamic and mechanism of No.1 HRYZ in model rats of hyperprolactinemia and HMG, while also studying the correlation between hyperprolactinemia and HMG preliminary. 
Materials and methods

Materials
Female Wistar rats weighing 200-220g were obtained from Hubei Center for Disease Control and Prevention, Wuhan, Hubei. The animals had free access to food and water, and were allowed to acclimatise for at least one week before use. All experiments conformed to the guidelines of the "Principles of Laboratory Animal Care" (NIH publication No.80-23, revised 1996) and the legislation of the People's Republic of China for the use and care of laboratory animals. Metoclopramide was obtained from Xuzhou Laien Pharmaceutical Co., Ltd. Bromocriptine methanesulfonate was obtained from Novartis Pharma Schweiz AG. Tamoxifen, a nonsteroidal anti-oestrogen, anticancer drug, was purchased from Ningbo Tianheng Pharmaceutical Co., Ltd. Rupisanjie caspule, a kind of frequently-used Chinese patent drug which is embodied in Chinese Pharmacopoeia (2010 edition) and has the curative effect for curing HMG in China, which was purchased from Shanxi Bailu Pharmaceutical Co., Ltd., was used as positive control for curing HMG. All other reagents and solvents were of analytical grade. 
NO
Preparation of model rats
The hyperprolactinemia rat model was performed as previously described with a little modification (Lin et al., 1988) .
Metoclopramide dihydrochloride injection was subcutaneously injected in the back of rats according to 50mg/kg body weight.
Experiment was performed at 9:00 and 15:00 respectively every day for five days. Estradiol was injected in the thigh muscle of the rats for twenty-five days, then was progesterone administered in like manner consecutively for five days (Rao et al., 1992; Milliken et al., 2002) . Meanwhile, tails of rats were clipped with tongs for thirty minutes every day. In this way, we prepared HMG rat model.
Experimental Groups and Treatments
The model rats of hyperprolactinemia were divided into six groups of ten individual groups: control, model group, Rupisanjie capsule (0.5g/kg). Each dose was dissolved in a 2-ml mixture of distilled water and administered intragastrally (i.g.) using a 5-ml syringe with a 4-cm long gavage needle through the mouth to the stomach. The initial dosage was based on body surface area and calculated from the daily human NO.1 HRYZ clinical dosage (FDA,2002) . Control, hyperprolactinemia model or HMG disease and integrated disease model rats received 2 ml of water. All group mice were intragastrically administrated for thirty days.
Blood serum collection and ELISA
At the end of thirty days, E 2, P, PRL, FSH, LH in the hyperprolactinemia rat serum and E 2 , P, PRL, FSH, LH, GnRH, 5-HT in the HMG rat serum were measured. All measurements were used by enzyme-linked immunosorbent assay (ELISA) kits according to the procedures recommended by the manufacturer (Shan hailichen, China).
Histological study
Tissues of mammary gland from each group were fixed in 10% buffered formalin, embedded in paraffin, sectioned into 4µm thickness, stained with Haematoxylin-Eosin (H-E) and Masson-Trichrome (M-T) and examined using optical microscopy. The severity of mammary gland hyperplasia was based on four parameters (hyperplasia of gland alveolus, lobule, shape and thickness of vessel and secretion).
Acute toxicities of NO.1 HRYZ in mice
Kunming mice (18-22 g ) were housed in cages at 22℃. Prior to the experiments, they were starved overnight with free access to water. NO.1 HRYZ decoction was prepared into freeze-dried powder (1g freeze-dried powder was equal to 16g NO.1 HRYZ crude drug). Test one: ten mice were divided into male and female half and given 43.1g/kg (200 times of adult dosage) or 34.9g/kg (162 times of adult dosage) freeze-dried powder every day for seven days. We observed the death after administration of twenty-four hours and seven days. Test two: twenty mice were divided into male and female half and given http://dx.doi.org/10.4314/ajtcam.v10i4.5 27 38.8g/kg (180 times of adult dosage) freeze-dried powder every day for fourteen days. We observed immediate toxicity reaction after administration and survival situation of mice in fourteen days.
Statistical analysis
Values are expressed as means±SEM. Multiple group comparisons were performed using one-way analysis of variance （ANOVA）followed by Dunnett's test to detect intergroup differences. P<0.05 was considered significant in all cases.
Results
Effect of NO.1 HRYZ on E 2 , P, PRL, FSH and LH levels in hyperprolactinemia rat serum
Hyperprolactinemia model rat significantly increased serum PRL concentration and decreased serum E 2 , P, FSH and LH concentrations (P＜0.05 vs. blank control). Such an increased PRL was significantly attenuated by treatment with bromocriptine, high-dose and middle-dose NO.1 HRYZ after one month administration (P＜0.05 vs. the "model" control).
Bromocriptine raised decreased E 2 , P significantly (P＜0.01 vs. the "model" control). E 2 of high-dose NO.1 HRYZ group increased remarkably (P＜0.05 vs. the "model" control), and so middle-dose NO.1 HRYZ group (P＜0.01 vs. the "model" control). Decreased P was increased by high-dose, middle-dose and low-dose NO.1 HRYZ (P＜0.05 vs. the "model" control).
Both of FSH (P＜0.01 vs. the "model" control) and LH (P＜0.05 vs. the "model" control) increased only in high-dose and middle-dose NO.1 HRYZ group (Figure 2-6 ). These illustrated that NO.1 HRYZ had obvious curative effect in treating hyperprolactinemia, which was even better than positive drug bromocriptine. (Figure 7A ), slight hyperplasia of lobules and gland alveolus, and a few secretions were found in the mammary gland of hyperprolactinemia model rats ( Figure 7B ). In bromocriptine-treated group at week 4, the hyperplasia of lobules and gland alveolus of mammary gland lessened, secretion and lymphocyte decreased in intracavitary ( Figure 7C ). The mammary gland of groups given high-dose NO.1 HRYZ and middle-dose NO.1 HRYZ recovered well.
There was no hyperplasia in gland alveolus and lobules of mammary gland, secretion and lymphocyte ( Figure 7D and E). A few gland alveolus and lobules hyperplasia were seen in the low-dose NO.1 HRYZ yet ( Figure 7F ). This illustrated that NO.1 HRYZ could inhibit the hyperplasia of mammary gland in hyperprolactinemia model rats effectively. Figure 14 ) and integrated disease model (P＜0.01 vs. blank control) rats significantly increased 5-HT concentration. Such a response was significantly attenuated by treatment with Rupisanjie, HRYZ inhibits chronic proliferative inflammation processes with a dose-dependent inhibition of granuloma formation in rat, and also has protective and therapeutic effects on HMG rats induced by oestrogen and progestogen. DNA, mammary cell sodiumt-ransport, and breast fatty acid synthetase activity (Malarkey et al., 1977) . However, relevant reports about the relationship between hyperprolactinemia and HMG were not found. In our experiment, the PRL concentration was determined in the hyperprolactinemia rat serum, and we found the PRL was much more than control rats.
Meanwhile, hyperplasia was found in the mammary gland of hyperprolactinemia model rats. Compared with control group, the serum PRL of HMG model rats increased significantly. These investigations demonstrated that there was close relationship between hyperprolactinemia and HMG, and hyperprolactinemia promoted the formation of HMG. Previously, doctors thought that HMG was induced by excessive E2 and insufficient P in patient serum, and ignored the action and importance of PRL on mammary gland (Shi and Zhou, 2010) . Our research revealed that PRL played a very important role in the formation of HMG, and hyperprolactinemia promoted the formation of HMG. However, the exact mechanism of PRL in the action of HMG is not clear. Although we only studied the hormone and morphology of mammary gland tissue in present experiment, more experiments such as hormone receptor and gene study between the two diseases are being performed by our researchers deeply.
In conclusion, the results presented significant therapeutic effects of NO.1 HRYZ by influencing sex hormone levels.
Hyperprolactinemia is closely correlated with HMG, and hyperprolactinemia promotes the formation of HMG. NO.1 HRYZ could be used for hyperprolactinemia and HMG treatment effectively. Further investigation about its real bioactive compounds is being studied by our researchers.
